The compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.

This website is intended for healthcare professionals only

Slide banner

225Ac felivotide mopaxetan (225Ac-PSMA-Trillium) (BAY 3563254)

See how this compound is being investigated across Bayer’s oncology pipeline

Explore the tumor types, areas of research, and clinical trials associated with this investigational compound.

254SQ

Compound Overview

Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is overexpressed in prostate cancer cells at all stages of the disease.1 Targeted alpha therapy is a potent and selective anticancer treatment approach that delivers highly ionizing alpha particle radiation to tumor cells and the tumor microenvironment, leading to anti-tumor activity while limiting exposure to surrounding normal tissue.2,3

225Ac felivotide mopaxetan (225Ac-PSMA-Trillium) (BAY 3563254) is a next-generation, small-molecule approach targeting PSMA that has the potential to provide a differentiated efficacy and safety profile due to its unique design.4 It is currently under phase I clinical investigation in patients with advanced metastatic castration-resistant prostate cancer.5-7

Tumor Type

Prostate cancer

Area of Research

Targeted radionuclide therapy

Clinical Trial

Tumor Type(s)

Phase

Status

Description

NCT Number

Prostate Cancer

I

Now Enrolling

A Phase 1 Open-label, First-in-human, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of 225Ac-PSMA-Trillium in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) (PAnTHA)

NCT06217822

Bayer’s Oncology Pipeline Brochure

Explore a comprehensive overview of Bayer's oncology pipeline, including investigational compounds, clinical trials, and areas of research.

Download BrochurePDF (1.45 MB)

The ongoing clinical trials listed on this website represent a comprehensive overview of Bayer's clinical pipeline in Oncology, including Bayer-sponsored research and collaborative research with academic centers, cooperative groups, and other global institutions.